Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348718 · ClinicalTrials.gov registry record
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
A clinical trial of Diabetic Kidney Disease (DKD), sponsored by Rubix LS.
- Active
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT07348718: Active study of Diabetic Kidney Disease (DKD), sponsored by Rubix LS.
NCT07348718 is a study of Diabetic Kidney Disease (DKD) that is active but no longer recruiting, run by Rubix LS. The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07348718, a study of Diabetic Kidney Disease (DKD), is active but no longer recruiting, sponsored by Rubix LS.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease. This prospective, observational patient registry will follow adults with type 2 diabetes and DKD who are receiving routine clinical care at participating sites, with intentional enrollment from underserved communities. Health information will be collected from medical records and brief questionnaires (including social and access factors) for up to 24 months to understand DKD progression, real-world treatment patterns, and outcomes. This study does not assign any treatment. With participant consent and appropriate privacy safeguards, de-identified registry data may be shared with researchers to accelerate evidence generation and inform future studies focused on improving outcomes.
Primary Outcome
Annualized change in kidney function, defined as the slope of estimated glomerular filtration rate (eGFR; mL/min/1.73m2/year) from baseline through 24 months. All available eGFR values obtained in routine clinical care during follow-up will be used. eGFR slope will be estimated using models that account for repeated measures (e.g., linear mixed-effects with random intercept/slope). Baseline eGFR is the value closest to enrollment; more negative slopes indicate faster decline.
Conditions Studied
Interventions
- DRUG Kidney-Protective Therapies Used in Routine Care
Study Locations (1)
Massachusetts
- Rubix LS - Lawrence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-04-01 |
What the registry record for NCT07348718 still lists
NCT07348718 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Diabetic Kidney Disease (DKD) appearing as the primary indexed condition, and to 1 intervention - of which Kidney-Protective Therapies Used in Routine Care is the first listed.
NCT07348718 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07348718 about?
NCT07348718 is a clinical study titled "Rubix LS Diabetic Kidney Disease (DKD) Registry Study". Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease. This prospective, observational patient registry will follow adults with type 2 diabetes and DKD who are receiving routine clinical care at part...
What is the current status of trial NCT07348718?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2025-12-15. Estimated completion is 2026-04-01.
What conditions does trial NCT07348718 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease (DKD).
What interventions are being tested in trial NCT07348718?
The interventions under investigation include: Kidney-Protective Therapies Used in Routine Care (DRUG).
Who is sponsoring clinical trial NCT07348718?
This trial is sponsored by Rubix LS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07348718 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease (DKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI